Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by miningfundion Mar 11, 2019 12:32pm
78 Views
Post# 29468389

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Oppenheimer: Initiating Coverage With Outperform Rating

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Oppenheimer: Initiating Coverage With Outperform RatingWhat I am expecting from HSM is what I get from every start-up I have invested in - a presentation for shareholders and investors that outlines management's view of how it sees its busines plan unfolding. I am not looking for precision, speculation, promises or hard facts - just management's best judgement (it can rely on the Forward-Looking disclaimer). Every start-up faces huge uncertainties and milestones beyond management's control, but that does not justify a black box investor relations approach.
vancity604 wrote: Yes, you are right, if there is no FDA approval it will be a big problem and that's what this board (and any Helius investor) has been talking about for 2+ years. Public companies (like Helius) are not allowed to speculate or make promises privately or publicly so I am not sure what you are hoping or expecting them to do.  



Bullboard Posts